The expression of the multidrug resistance-associated glycoprotein in B-cell chronic lymphocytic leukaemia

M. Michieli, D. Raspadori, D. Damiani, A. Geromin, C. Gallizia, A. Michelutti, R. Fanin, G. Fasola, D. Russo, P. Tazzari, S. Pileri, F. Mallardi, M. Baccarani

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

The expression of the multidrug resistance (MDR)-associated 170 kDa glycoprotein (p170) was investigated in 63 cases of B-cell chronic lymphocytic leukaemia (CLL), with two monoclonal antibodies (MRK-16 and C-219). By immunocytochemistry with MRK-16 (63 cases), the great majority of the cells was positive, with a weak reaction in 61% of cases and a strong reaction in 39% of cases. By flow cytometry, the proportion of positive cells was 39 ± 25% with MRK-16 (63 cases), and 23 ± 22% with C-219 (36 cases). The expression of p170 in leukaemic B-lymphocytes suggests that also in B-CLL the development of MDR can have some therapeutic relevance. By either method the proportion of positive cells was not related to prior treatment, time from diagnosis, absolute lymphocyte count, and clinical stage (Rai's and workshop classifications), but 12 patients who were under treatment with α-interferon had more positive cells than the other ones.

Original languageEnglish
Pages (from-to)460-465
Number of pages6
JournalBritish Journal of Haematology
Volume77
Issue number4
Publication statusPublished - 1991

Fingerprint

Multiple Drug Resistance
B-Cell Chronic Lymphocytic Leukemia
Glycoproteins
Lymphocyte Count
Interferons
Flow Cytometry
B-Lymphocytes
Therapeutics
Immunohistochemistry
Monoclonal Antibodies
Education

ASJC Scopus subject areas

  • Hematology

Cite this

Michieli, M., Raspadori, D., Damiani, D., Geromin, A., Gallizia, C., Michelutti, A., ... Baccarani, M. (1991). The expression of the multidrug resistance-associated glycoprotein in B-cell chronic lymphocytic leukaemia. British Journal of Haematology, 77(4), 460-465.

The expression of the multidrug resistance-associated glycoprotein in B-cell chronic lymphocytic leukaemia. / Michieli, M.; Raspadori, D.; Damiani, D.; Geromin, A.; Gallizia, C.; Michelutti, A.; Fanin, R.; Fasola, G.; Russo, D.; Tazzari, P.; Pileri, S.; Mallardi, F.; Baccarani, M.

In: British Journal of Haematology, Vol. 77, No. 4, 1991, p. 460-465.

Research output: Contribution to journalArticle

Michieli, M, Raspadori, D, Damiani, D, Geromin, A, Gallizia, C, Michelutti, A, Fanin, R, Fasola, G, Russo, D, Tazzari, P, Pileri, S, Mallardi, F & Baccarani, M 1991, 'The expression of the multidrug resistance-associated glycoprotein in B-cell chronic lymphocytic leukaemia', British Journal of Haematology, vol. 77, no. 4, pp. 460-465.
Michieli, M. ; Raspadori, D. ; Damiani, D. ; Geromin, A. ; Gallizia, C. ; Michelutti, A. ; Fanin, R. ; Fasola, G. ; Russo, D. ; Tazzari, P. ; Pileri, S. ; Mallardi, F. ; Baccarani, M. / The expression of the multidrug resistance-associated glycoprotein in B-cell chronic lymphocytic leukaemia. In: British Journal of Haematology. 1991 ; Vol. 77, No. 4. pp. 460-465.
@article{1c0c7559d983449498cb4ab8ee4534f0,
title = "The expression of the multidrug resistance-associated glycoprotein in B-cell chronic lymphocytic leukaemia",
abstract = "The expression of the multidrug resistance (MDR)-associated 170 kDa glycoprotein (p170) was investigated in 63 cases of B-cell chronic lymphocytic leukaemia (CLL), with two monoclonal antibodies (MRK-16 and C-219). By immunocytochemistry with MRK-16 (63 cases), the great majority of the cells was positive, with a weak reaction in 61{\%} of cases and a strong reaction in 39{\%} of cases. By flow cytometry, the proportion of positive cells was 39 ± 25{\%} with MRK-16 (63 cases), and 23 ± 22{\%} with C-219 (36 cases). The expression of p170 in leukaemic B-lymphocytes suggests that also in B-CLL the development of MDR can have some therapeutic relevance. By either method the proportion of positive cells was not related to prior treatment, time from diagnosis, absolute lymphocyte count, and clinical stage (Rai's and workshop classifications), but 12 patients who were under treatment with α-interferon had more positive cells than the other ones.",
author = "M. Michieli and D. Raspadori and D. Damiani and A. Geromin and C. Gallizia and A. Michelutti and R. Fanin and G. Fasola and D. Russo and P. Tazzari and S. Pileri and F. Mallardi and M. Baccarani",
year = "1991",
language = "English",
volume = "77",
pages = "460--465",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "4",

}

TY - JOUR

T1 - The expression of the multidrug resistance-associated glycoprotein in B-cell chronic lymphocytic leukaemia

AU - Michieli, M.

AU - Raspadori, D.

AU - Damiani, D.

AU - Geromin, A.

AU - Gallizia, C.

AU - Michelutti, A.

AU - Fanin, R.

AU - Fasola, G.

AU - Russo, D.

AU - Tazzari, P.

AU - Pileri, S.

AU - Mallardi, F.

AU - Baccarani, M.

PY - 1991

Y1 - 1991

N2 - The expression of the multidrug resistance (MDR)-associated 170 kDa glycoprotein (p170) was investigated in 63 cases of B-cell chronic lymphocytic leukaemia (CLL), with two monoclonal antibodies (MRK-16 and C-219). By immunocytochemistry with MRK-16 (63 cases), the great majority of the cells was positive, with a weak reaction in 61% of cases and a strong reaction in 39% of cases. By flow cytometry, the proportion of positive cells was 39 ± 25% with MRK-16 (63 cases), and 23 ± 22% with C-219 (36 cases). The expression of p170 in leukaemic B-lymphocytes suggests that also in B-CLL the development of MDR can have some therapeutic relevance. By either method the proportion of positive cells was not related to prior treatment, time from diagnosis, absolute lymphocyte count, and clinical stage (Rai's and workshop classifications), but 12 patients who were under treatment with α-interferon had more positive cells than the other ones.

AB - The expression of the multidrug resistance (MDR)-associated 170 kDa glycoprotein (p170) was investigated in 63 cases of B-cell chronic lymphocytic leukaemia (CLL), with two monoclonal antibodies (MRK-16 and C-219). By immunocytochemistry with MRK-16 (63 cases), the great majority of the cells was positive, with a weak reaction in 61% of cases and a strong reaction in 39% of cases. By flow cytometry, the proportion of positive cells was 39 ± 25% with MRK-16 (63 cases), and 23 ± 22% with C-219 (36 cases). The expression of p170 in leukaemic B-lymphocytes suggests that also in B-CLL the development of MDR can have some therapeutic relevance. By either method the proportion of positive cells was not related to prior treatment, time from diagnosis, absolute lymphocyte count, and clinical stage (Rai's and workshop classifications), but 12 patients who were under treatment with α-interferon had more positive cells than the other ones.

UR - http://www.scopus.com/inward/record.url?scp=0025884455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025884455&partnerID=8YFLogxK

M3 - Article

C2 - 1673863

AN - SCOPUS:0025884455

VL - 77

SP - 460

EP - 465

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 4

ER -